Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Riot Platforms Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.34 (market cap $8.04B), while Riot Platforms Inc trades at $20.03 (market cap $7.64B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and Riot Platforms Inc are close in size by market cap. Which is the better fit depends on your goals.
| BIO | RIOT | |
|---|---|---|
Market Cap | $8.04B | $7.64B |
Sector | Health | Technology |
52-Week High | $339.75 | $28.67 |
52-Week Low | $241.71 | $11.03 |
Enterprise Value | $7.85B | $8.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
RIOT stock trades at $20.19, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $663.18 million in 2025, with a negative net income margin of -132.76%, though revenue reached $647.44 million. Analyst consensus remains strongly bullish with a $27.86 price target, supported by 17 buy ratings. Recent news highlights volatility amid broader crypto stock trends and a strategic pivot toward high-performance computing.
The outlook is mixed: strong analyst support and a strategic shift to data centers offer upside, but persistent losses, negative cash flow from operations, and sensitivity to Bitcoin market swings pose significant risks. Investors should weigh the high valuation multiples against the company's unprofitability and execution challenges in its expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
